CD274 and neoplasm: Recent studies have proposed PDL1 expression, tumor mutational burden, and DNA mismatch repair deficiency as biomarkers for anti-PD-1 therapy (Teng et al., 2018; Darvin et al., 2018; El-Osta & Jafri, 2019).